$62,500* for LSD1 Inhibition to Treat T-cell Acute Lymphoblastic Leukemia/Lymphoma
Michael Engel, MD/PhD - University of Utah, Salt Lake City
With our proposed experiments, we will confirm that SP-2577 kills T-AL/L cells isolated from patients and transplanted into mice. We will also devise tests that show SP-2577 “hits its target” (LSD1) and may predict which patients will respond to the drug.
$25,000* for Developing Targeted Immunotherapy Against Pediatric Acute Myeloid Leukemia
Dr. Melinda Biernacki, MD - Fred Hutchinson Cancer Research Center, Seattle, WA
To develop new T cell therapy for pediatric AML, we propose to identify AML-specific neoepitopes by merging state-of-the-art gene sequencing of leukemia-specific variants with established HLA-binding prediction algorithms and a highthroughput immune-reactivity screen.